爵士製藥 JAZZ 深 滬
等待開盤 01-29 09:30:00 美东时间
165.41
-2.440
-1.45%
華盛通- 最 高168.05
- 今 開167.34
- 成交量 89.32万股
- 最 低 164.29
- 昨 收 167.85
- 總市值 100.51亿
- 52周最高 182.99
- 市盈率 靜 19.13
- 換手率 0.00%
- 52周最低 95.49
- 委 比 -77.33%
- 總股本 6076.51万
- 歷史最高 194.73
- 量 比 1.09
- 振 幅 2.24%
- 歷史最低 31.87
- 每 手 1
- 風險率 21.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Zymeworks Announces Participation in Upcoming Investor Conferences
<p>Zymeworks Inc. (Nasdaq: ZYME), a global biotechnology company managing licensed healthcare assets and developing novel biotherapeutics, announces its management will participate in four upcoming investor conferences in 2026: Citi’s Virtual Oncology Summit (February 18-19), TD Cowen Conference (March 2 in Boston), Leerink Conference (March 9 in Miami), and Citizens Life Science Conference (March 11 in Miami). The company focuses on improving tr...
01-27 11:00
美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
Needham Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $235
Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $210 to $235.
01-12 17:46
快讯 | Jazz Pharmaceuticals 任命Thomas Riga为首席商务官
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
01-09 05:05
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions DUBLIN, Jan. 8, 2026 /PRNe...
01-09 05:05
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
DUBLIN, Dec. 17, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following investor events: Zanidatamab HERIZON-GEA-01 I...
2025-12-18 05:15
美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
2025-12-11 10:33
Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Raises Price Target to $219
Piper Sandler analyst David Amsellem reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $147 to $219.
2025-12-11 00:47
Jazz Pharmaceuticals To Present Phase 3 Results Of Ziihera Combinations In First-Line HER2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma
Late-breaking HERIZON-GEA-01 presentation highlights the expanding clinical profile of Ziihera across HER2-driven gastrointestinal cancers Jazz to host investor webcast on Friday, January 9, 2026, to review data
2025-12-03 05:12
